NCT07393425 2026-02-06
Neoadjuvant Trastuzumab Deruxtecan (SHR-A1811) + Pertuzumab in HER2+ Breast Cancer
Shanghai Jiao Tong University School of Medicine
Phase 2 Recruiting
Clinical Trials
9 trialsNCT07340398 2026-01-21
TAYLOR
Second Affiliated Hospital, School of Medicine, Zhejiang University
Phase 2 Recruiting
NCT05751018 2025-12-02
Phase II Clinical Study of Pyrotinib in First-line Treatment of Primary HER2-amplified/Mutated Advanced Non-small Cell Lung Cancer
Peking Union Medical College Hospital
Phase 2 Recruiting
NCT05910398 2025-11-18
CORINNE-PI
RenJi Hospital
Phase 3 Recruiting
NCT07180082 2025-11-18
CORIN-PYRA
RenJi Hospital
Phase 2 Recruiting
NCT06145308 2025-09-15
Precision Treatment of Recurrent/Metastatic Salivary Gland Carcinoma Guided by Molecular Typing
Peking Union Medical College
Phase 2 Recruiting
NCT04254263 2025-09-11
ATP
RenJi Hospital
Phase 3 Recruiting
NCT07065435 2025-07-15
RC48 Plus Bevacizumab or Pyrotinib in HER2-Positive Metastatic Breast Cancer After T-DXd Failure: A Phase II Study
The First Affiliated Hospital with Nanjing Medical University
Phase 2 Recruiting
NCT06958627 2025-05-06
any
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 2/3 Recruiting